Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional

A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

ClinicalTrials.gov ID: NCT00000969

Public ClinicalTrials.gov record NCT00000969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate and compare the effectiveness and toxicity associated with didanosine ( ddI ) and zalcitabine ( dideoxycytidine; ddC ) in patients with HIV infection who are intolerant of or have failed zidovudine ( AZT ) therapy. Alternative and less toxic treatments need to be investigated for the treatment of HIV infection. Studies have shown that the dideoxynucleosides ddI and ddC may be effective antiretroviral agents in the treatment of HIV-infected individuals. However, ddI and ddC have yet to be compared on the basis of patient survival, drug tolerance, immunologic and virologic effectiveness, and the incidence of opportunistic infection or opportunistic malignancy. Results of this study will yield information regarding the relative therapeutic benefits and toxicities of each drug while providing alternative treatment to patients who are unable to tolerate or have had progression of disease while on AZT.

Study identification

NCT ID
NCT00000969
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Enrollment
400 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Aug 31, 1992
Last update posted
Nov 3, 2021

Ends 1992

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
14
Facility City State ZIP Site status
Community Consortium of San Francisco San Francisco California 94110
Denver CPCRA / Denver Public Hlth Denver Colorado 802044507
Hill Health Corp New Haven Connecticut 06519
Wilmington Hosp / Med Ctr of Delaware Wilmington Delaware 19899
Veterans Administration Med Ctr / Regional AIDS Program Washington D.C. District of Columbia 20422
AIDS Research Consortium of Atlanta Atlanta Georgia 30308
AIDS Research Alliance - Chicago Chicago Illinois 60657
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med New Orleans Louisiana 70112
Comprehensive AIDS Alliance of Detroit Detroit Michigan 48201
Henry Ford Hosp Detroit Michigan 48202
North Jersey Community Research Initiative Newark New Jersey 071032842
Clinical Directors Network of Region II New York New York 10011
Harlem AIDS Treatment Group / Harlem Hosp Ctr New York New York 10037
Bronx Lebanon Hosp Ctr The Bronx New York 10456
Portland Veterans Adm Med Ctr / Rsch & Education Grp Portland Oregon 972109951
Richmond AIDS Consortium Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00000969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2021 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00000969 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →